

TG THERAPEUTICS, INC.  
Form 8-K  
March 11, 2015

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D.C. 20549**

---

**FORM 8-K**

---

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934**

Date of report (Date of earliest event reported): **March 11, 2015**

**TG Therapeutics, Inc.**

(Exact Name of Registrant as Specified in Charter)

**Delaware**

**001-32639**

**36-3898269**

(State or Other Jurisdiction (Commission File Number) (IRS Employer Identification No.))

of Incorporation)

**3 Columbus Circle, 15<sup>th</sup> Floor**

**New York, New York 10019**

(Address of Principal Executive Offices)

**(212) 554-4484**

(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act.
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act.
- Pre-commencement communications pursuant to Rule 14d-2b under the Exchange Act.
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

**Item 2.02. Results of Operations and Financial Condition.**

On March 11, 2015, TG Therapeutics, Inc. (“TG” or the “Company”) issued a press release announcing results of operations for the fourth quarter and year ended December 31, 2014. TG also announced that on Thursday, March 12, 2015 at 8:30am EST, TG would host an investor conference call during which the Company would provide a brief financial overview of its fourth quarter and year end 2014 financial results and a business outlook for 2015. A copy of such press release is being furnished as Exhibit 99.1.

**Item 9.01 Financial Statements And Exhibits.**

(d)

Exhibits.

99.1 Press release issued by TG Therapeutics, Inc., dated March 11, 2015.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

TG Therapeutics,  
Inc.  
(Registrant)

Date: March 11, 2015

By: /s/ Sean A.  
Power  
Sean A.  
Power  
Chief  
Financial  
Officer

INDEX TO EXHIBITS

**Exhibit**

	<b><u>Number</u></b>	<b><u>Description</u></b>
	99.1	Press release issued by TG Therapeutics, Inc., dated March 11, 2015.